Berenson J R, Lipton A
West Los Angeles VA Medical Center, California, USA.
Oncology (Williston Park). 1998 Nov;12(11):1573-9; discussion 1579-81.
Tumor-induced osteolysis or lytic bone disease is mediated by osteoclast activation. Osteoclasts can be activated directly by products produced by tumors or indirectly through other nonmalignant cells. By reducing osteoclastic activity, bisphosphonates inhibit bone resorption. Since these agents had demonstrated efficacy in treating other diseases associated with increased bone resorption, including cancer-related hypercalcemia and Paget's disease of bone, studies were initiated to explore the use of bisphosphonates in patients with osteolytic bone metastases. Recent, large, randomized, double-blind studies have shown the efficacy of these agents in reducing skeletal complications in patients with bone metastases from both breast cancer and multiple myeloma.
肿瘤诱导的骨质溶解或溶骨性骨病是由破骨细胞激活介导的。破骨细胞可被肿瘤产生的产物直接激活，或通过其他非恶性细胞间接激活。双膦酸盐通过降低破骨细胞活性来抑制骨吸收。由于这些药物已在治疗其他与骨吸收增加相关的疾病（包括癌症相关的高钙血症和骨Paget病）中显示出疗效，因此开展了研究以探索双膦酸盐在溶骨性骨转移患者中的应用。最近的大型随机双盲研究表明，这些药物在降低乳腺癌和多发性骨髓瘤骨转移患者的骨骼并发症方面具有疗效。
